人工智能共聚类算法辅助药物警戒监测
研究采用动态潜在块模型(dLBM)对2012年1月1日至2022年2月28日期间45 269份区域性药物不良反应报告进行无监督共聚类,将报告按时间、药物和不良反应分组,识别出三类社会关注问题和特定药物-不良反应关系如抗血小板药、抗凝药与出血的关联,认为共聚类是探索大型药物警戒数据库的有前景工具。
要点
- dLBM将45 269份报告聚为10个时间、10个不良反应和9个药物集合。
- 检测到与COVID-19疫苗等相关的媒体炒作引发报告激增问题。
- 共聚类可无监督地发现和强化药物安全信号。
核心结论
- 共聚类和dLBM是探索大型药物警戒数据库的有前景工具,可无监督地检测、探索和强化安全信号,便于分析报告激增。
研究设计与样本
- 研究使用基于时间依赖共聚类生成方法的动态潜在块模型(dLBM),对2012年1月1日至2022年2月28日期间所有区域性药物不良反应报告(n=45 269)进行汇总分析。
主要发现
- 模型将所有报告聚类为10个时间集合、10个不良反应集合和9个药物集合。
- 基于聚类检测到三个突出的社会问题,继发于公共卫生对药物安全的关注,包括媒体对COVID-19疫苗感知安全性的显著炒作。
- dLBM还突出了某些特定的药物-不良反应关系,如抗血小板药、抗凝药与出血之间的关联。
临床怎么用
- 可利用共聚类方法无监督地探索大型药物警戒数据库,辅助检测和强化药物安全信号。
- 可借助该方法应对报告数量激增的情况,如社交媒体引发的报告浪潮。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Monitoring drug safety in real-world settings is the primary aim of pharmacovigilance. Frequent adverse drug reactions (ADRs) are usually identified during drug development. Rare ones are mostly characterized through post-marketing scrutiny, increasingly with the use of data mining and disproportionality approaches, which lead to new drug safety signals. Nonetheless, waves of excessive numbers of reports, often stirred up by social media, may overwhelm and distort this process, as observed recently with levothyroxine or COVID-19 vaccines. As human resources become rarer in the field of pharmacovigilance, we aimed to evaluate the performance of an unsupervised co-clustering method to help the monitoring of drug safety. METHODS: A dynamic latent block model (dLBM), based on a time-dependent co-clustering generative method, was used to summarize all regional ADR reports (n = 45 269) issued between 1 January 2012 and 28 February 2022. After analysis of their intra and extra interrelationships, all reports were grouped into different cluster types (time, drug, ADR). RESULTS: Our model clustered all reports in 10 time, 10 ADR and 9 drug collections. Based on such clustering, three prominent societal problems were detected, subsequent to public health concerns about drug safety, including a prominent media hype about the perceived safety of COVID-19 vaccines. The dLBM also highlighted some specific drug-ADR relationships, such as the association between antiplatelets, anticoagulants and bleeding. CONCLUSIONS: Co-clustering and dLBM appear as promising tools to explore large pharmacovigilance databases. They allow, 'unsupervisedly', the detection, exploration and strengthening of safety signals, facilitating the analysis of massive upsurges of reports.
引用
- Destere A, Marchello G, Merino D, et al. An artificial intelligence algorithm for co-clustering to help in pharmacovigilance before and during the COVID-19 pandemic. Br J Clin Pharmacol. 2024. PMID: 38332645. doi:10.1111/bcp.16012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。